Titlebook: Concepts, Clinical Developments, and Therapeutic Advances in Cancer Chemotherapy; F. M. Muggia Book 1987 Martinus Nijhoff Publishers, Bost

易怒

Metabolites of tiazofurin as mediators of its biochemical and pharmacologic effectsounds [1,2]. In fact, the agent does exhibit a modest to moderate degree of activity against several pathogenic viruses [2,3]. However, at the time, this activity apparently was not judged sufficient to warrant development of the drug towards clinical trials. With the advent of managerial changes at

胖人手藝好

Extragonadal and central nervous system germ cell tumors: A review of diagnostic and therapeutic strpproximately 2.1 to 3.1 cases per 100,000 males in the United States and Great Britain [1]. Amongst those cases of germ cell tumors about 1% to 2% have an extragonadal origin. These tumors possess a similar spectrum of pathologies as their primary testicular counterparts [2–6] and include all types

intertwine

Role of preclinical pharmacology in phase I clinical trials: Considerations of schedule-dependencece, and the most familiar examples occur with the use of methotrexate (MTX), fluorodeoxyuridine (FdUrd), and cytosine arabinoside (ara-C). The general motivation for the study of schedule-dependence is to improve the therapeutic index of a drug, i.e., to maximize the ratio of therapeutic effects to

ear-canal

MUMP

IRATE

Chemotherapy for malignant intracranial tumorshwannomas which carried a high surgical mortality rate in Cushing’s era are now removed safely and successfully as are pituitary tumors and most meningiomas. The impact of these technical advances on the management of the malignant intracranial tumors, in particular on the glioblastoma multiforme, t